Estimation of Probability of Malignancy Using a Logistic Model Combining Physical Examination, Ultrasound, Serum CA 125, and Serum CA 72-4 in Postmenopausal Women with a Pelvic Mass: An International Multicenter Study

This publication has 39 references indexed in Scilit:

• Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases
  American Journal of Obstetrics and Gynecology, 1994
• Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study
  Cancer, 1994
• The concomitant determination of different serum tumor markers in epithelial ovarian cancer: Relevance for monitoring the response to chemotherapy and follow-up of patients
  Gynecologic Oncology, 1992
• The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis
  Gynecologic Oncology, 1992
• Low frequency and low level of elevation of serum CA 72-4 in human carcinomas in comparison with established tumor markers
  Journal of Clinical Laboratory Analysis, 1992
• Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A lingitudinal study
  Cancer, 1991
• Coordinate elevation of serum markers in ovarian cancer but not in benign disease
  Cancer, 1991
• Ca 72‐4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers
  International Journal of Cancer, 1990
• A radioimmunoassay for the detection of a human tumor‐associated glycoprotein (tag‐72) using monoclonal antibody B72.3
  International Journal of Cancer, 1986
• A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populations
  International Journal of Cancer, 1982